A comprehensive view of Takeda Pharmaceutical Co. Ltd.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Takeda’s injectable Takhzyro lanadelumab-flyo now available in US in single-dose prefilled syringes to prevent attacks of hereditary angioedema in adult, pediatric patients 12 years of age and older; HAE affects 1 in 50,000 people worldwide
Published: April 25, 2022 by ENP Newswire
Takeda announces approval in Japan for TAKHZYRO subcutaneous injection for prevention of acute attacks of hereditary angioedema; condition is a rare genetic disorder that causes recurring swelling
Published: March 28, 2022 by Takeda Pharmaceutical Co. Ltd.
A combination of remdesivir with hIVIG not more effective than remdesivir alone for treating adults hospitalized with COVID-19; safety outcomes 1.6 time worse for patients who had SARS-CoV-2 neutralizing antibodies before hIVIG treatment; study
Published: February 16, 2022 by CDC & FDA Daily
Takeda announces FDA approval of the TAKHZYRO injection single-dose prefilled syringe for treatment of hereditary angioedema; approval offers new option in addition to vial injection
Published: February 09, 2022 by Takeda Pharmaceutical Co. Ltd.
Takeda names Ramona Sequeira as president, Global Portfolio Division; Julie Kim as president of U.S. Business Unit and U.S. country head; and Giles Platford as president of PDT Business Unit
Published: February 03, 2022 by Takeda Pharmaceutical Co. Ltd.

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count